Eisai’s thyroid cancer drug Lenvima gets approval in Europe
Lenvima is an orally administered molecular targeted agent which inhibits the activities of several different molecules including VEGFR, FGFR, RET, KIT and PDGFR. It particularly inhibits VEGFR, FGFR